Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138280 | 1.00 | KMT2A (0.56) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL27757196 | 1.00 | KMT2A (0.56) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1706675 | 1.00 | KMT2A (0.56) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL7686303 | 0.98 | KMT2A (0.54) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL8687505 | 0.98 | KMT2A (0.54) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL8687912 | 0.98 | KMT2A (0.54) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7933798 | 0.93 | KMT2A (0.50) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7924569 | 0.91 | KMT2A (0.49) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7929531 | 0.91 | KMT2A (0.49) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3260466 | 0.89 | GAA (0.57) | CYP1A2CYP2C9CYP2C19TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113233972-B | Synthesis method of (R) -2-benzyloxy propionic acid and intermediate thereof | 南京红杉生物科技有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-109796368-B | Synthesis method of N' - [ (2S,3S) -2- (benzyloxy) pentan-3-yl ] formylhydrazine | 浙江大学宁波理工学院 | 2021-11-02 | — | — | CN | claimed |
| CN-113233972-A | Synthesis method of (R) -2-benzyloxy propionic acid and intermediate thereof | 南京红杉生物科技有限公司 | 2021-08-10 | — | — | CN | claimed |
| CN-109651187-B | Synthesis method of (S) -N' - (2-benzyloxypropylene) formylhydrazine | 宁波新极新材料科技有限公司 | 2021-07-09 | — | — | CN | claimed |
| CN-108101759-B | Method for synthesizing (S) -2-benzyloxy propionaldehyde | 宁波新凯生物科技有限公司 | 2021-06-11 | — | — | CN | claimed |
| US-20200360317-A1 | CARBOXYLIC ACIDS FOR TREATING/PREVENTING A SKIN DISEASE | PROPONENT BIOTECH GMBH (CH) | 2020-11-19 | — | — | US | claimed |
| CN-108586280-B | Method for synthesizing N' - [ (2S,3S) -2- (benzyloxy) pentan-3-yl ] formylhydrazine | 宁波新极新材料科技有限公司 | 2020-11-10 | — | — | CN | claimed |
| CN-108191703-B | Method for synthesizing (S) -N' - (2-benzyloxy propylene) formylhydrazine | 宁波新极新材料科技有限公司 | 2020-07-07 | — | — | CN | claimed |
| US-20190160030-A1 | CARBOXYLIC ACIDS FOR EARLY CHILDHOOD APPLICATION | PROPONENT BIOTECH GMBH (CH) | 2019-05-30 | — | — | US | claimed |
| CN-109796368-A | A kind of synthetic method of N '-[(2S, 3S) -2-(benzyloxy) amyl- 3- yl] formylhydrazine | 浙江大学宁波理工学院 | 2019-05-24 | — | — | CN | claimed |
| EP-2758385-B1 | PROCESS FOR THE PREPARATION OF TRIAZOLE ANTIFUNGAL DRUG, ITS INTERMEDIATES AND POLYMORPHS THEREOF | MSN LAB LTD (IN) | 2018-03-28 | — | — | EP | claimed |
| US-20160250168-A1 | ESTERS OF SHORT CHAINS FATTY ACIDS FOR USE IN THE TREATMENT OF IMMUNOGENIC DISORDERS | PROPONENT BIOTECH GMBH (CH) | 2016-09-01 | — | — | US | claimed |
| US-20150246015-A1 | Esters of Short Chains Fatty Acids for Use in the Treatment of Immunogenic Disorders | PROPONENT BIOTECH GMBH (CH) | 2015-09-03 | — | — | US | claimed |
| EP-2903608-A1 | ESTERS OF SHORT CHAINS FATTY ACIDS FOR USE IN THE TREATMENT OF IMMUNOGENIC DISORDERS | Proponent Biotech GmbH (CH) | 2015-08-12 | — | — | EP | claimed |
| CN-102603550-B | Preparation method of intermediate BOPTA (4-hydroxy-5,8,11-tricarboxymethyl-1-phenyl-2-oxa-5,8,11-triazanaphthalenetridecane-13-acid) | FOSHAN PRIZEN MEDICAL TECHNOLOGY CO LTD | 2014-11-26 | — | — | CN | claimed |
| US-20140343285-A1 | Process for the Preparation of Triazole Antifungal Drug, Its Intermediates and Polymorphs Thereof | MSN LABORATORIES LIMITED (IN) | 2014-11-20 | — | — | US | claimed |
| EP-2758385-A2 | PROCESS FOR THE PREPARATION OF TRIAZOLE ANTIFUNGAL DRUG, ITS INTERMEDIATES AND POLYMORPHS THEREOF | MSN Laboratories Limited (IN) | 2014-07-30 | — | — | EP | claimed |
| WO-2014053592-A1 | ESTERS OF SHORT CHAINS FATTY ACIDS FOR USE IN THE TREATMENT OF IMMUNOGENIC DISORDERS | PROPONENT BIOTECH GMBH (CH) | 2014-04-10 | — | — | WO | claimed |
| WO-2013042138-A2 | PROCESS FOR THE PREPARATION OF TRIAZOLE ANTIFUNGAL DRUG, ITS INTERMEDIATES AND POLYMORPHS THEREOF | MSN LABORATORIES LIMITED (IN) | 2013-03-28 | — | — | WO | claimed |
| WO-2012131069-A1 | SHORT CHAIN FATTY ACIDS AND THEIR DERIVATIVES FOR USE IN TREATMENT IMMUNOGENIC DISORDERS | PROPONENT BIOTECH GMBH (CH) | 2012-10-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250168-A1 | ESTERS OF SHORT CHAINS FATTY ACIDS FOR USE IN THE TREATMENT OF IMMUNOGENIC DISORDERS | TSLP, HLA-DRB1, LTA | KMT2A 2312/4885CYP1A2 2231/4885SLC1A3 764/4885 |
| US-20140343285-A1 | Process for the Preparation of Triazole Antifungal Drug, Its Intermediates and Polymorphs Thereof | CYP3A4, CYP51A1, CYP1B1 | KMT2A 3861/4885CYP1A2 11/4885SLC1A3 4320/4885 |
| US-20150246015-A1 | Esters of Short Chains Fatty Acids for Use in the Treatment of Immunogenic Disorders | TSLP, HLA-DRB1, LTA | KMT2A 2312/4885CYP1A2 2231/4885SLC1A3 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.